<DOC>
	<DOC>NCT00821418</DOC>
	<brief_summary>The purpose of the study is to assess the safety and the effect of treatment by PulseHaler™ on patients with COPD, as measured by the change from baseline in full pulmonary functions, oxygen saturation, exercise tolerance and health related quality of life; and to assess the ease of use of PulseHaler™ by the patients.</brief_summary>
	<brief_title>Assessment of Treatment With PulseHaler on Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Diagnosis of COPD Diagnosis established for at least 1 year; Postbronchodilator FEV1/FVC &lt; 0.7 Post bronchodilator FEV1 &lt;70% predicted Age: 40 years or older Smoking cigarettes, at least 10PY Patient signed the informed consent form Bullous Emphysema (ruled out by recent CT) Hospitalization due to exacerbation of COPD within the last 3 months Upper respiratory infection and/or exacerbation of COPD in the last 4 weeks Systemic steroid treatment in the last 4 weeks Women at the age of fertility, who are pregnant, or plan pregnancy, or do not use contraceptive. Severe cardiac disease, e.g., CHF grade 3 or higher Acute MI within last 3 months CABG within last 3 months Other severe systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>